Web Images Videos Maps News Shopping Gmail more »
Sign in
Scholar Home  
  Advanced Scholar Search
Scholar Preferences
Scholar Results 1 - 5 of 5 citing Wiegand: Intravitreal bevacizumab (Avastin) treatment of choroidal neovascularisation in.... (0.06 sec) 

Angioid streaks, clinical course, complications, and current therapeutic management


… , C Koutsandrea, G Kalantzis, D Karagiannis, … - Therapeutics and Clinical Risk Management, 2009 - pubmedcentral.nih.gov
Angioid streaks are visible irregular crack-like dehiscences in Bruch's membrane
that are associated with atrophic degeneration of the overlying retinal
pigmented epithelium. Angioid streaks may be associated with pseudoxanthoma ...
Cited by 1 - Related articles - All 6 versions

[PDF] Bevacizumab (Avastin®) and Ranibizumab (Lucentis®) in the management of non-AMD …


W Horsley - netag.nhs.uk
• Choroidal neovascularisation can be due to numerous causes other than
age-related macular degeneration although these represent a minority of overall
cases compared with those due to AMD. ... • Within NHS North East about ...
Related articles - View as HTML

Intravitreal bevacizumab for choroidal neovascularisation secondary to causes other than …


B Gupta, M Elagouz, S Sivaprasad - Eye, 2009 - nature.com
Choroidal neovascularisation (CNV) is characterised by new blood vessel growth
under the retina that usually results in significant visual impairment when the
fovea is involved. Though CNV is more commonly associated with age-related ...
Related articles - All 3 versions

[CITATION] Intravitreal ranibizumab for choroidal neovascularisation secondary to angioid streaks


S Kang, YJ Roh - Eye, 2009 - nature.com
Jump to main content; Jump to navigation; nature.com homepage; Publications AZ index;
Browse by subject. My account; Submit manuscript; Register; Subscribe; RCOphth ...
Related articles - All 3 versions

Long-term Results of Intravitreal Bevacizumab Injection for Choroidal Neovascularization …


M Sawa, F Gomi, M Tsujikawa, H Sakaguchi, … - American Journal of Ophthalmology, 2009 - Elsevier
The mean follow-up was 19 months (range, 12 to 24 months). The mean number of
injections for primary CNV was 4.5 (range, 1 to 9). The mean preoperative BCVA
(decimal equivalent) was 0.39 (range, 0.08 to 1.5) and 0.47 (range, 0.06 to ...
Related articles - All 12 versions


 


Go to Google Home - About Google - About Google Scholar

©2009 Google